Next-generation sequencing (NGS) can simultaneously sequence millions or even billions of DNA molecules to achieve large-scale, high-throughput sequencing, which is a revolutionary advancement after Sanger sequencing. At present, NGS is mainly used in clinical driver gene sequencing, which is an important link in the precise diagnosis and treatment of tumors.

FDA has approved 7 NGS products for precision medicine. Combining with the clinical needs of solid tumor diagnosis and treatment, MEDx Translational Meidicine (Simply MEDx ) has independently developed a variety of NGS Panel products: Med1CDx (601 genes), OncoCDx (191 genes) , etc.

l  OncoCDx: 191-Gene Panel for Solid Tumors

n  Whole Exons of 191 Genes

n  Targeted Therapy (Sensitive/Resistant)-89 Genes

n  Chemotherapy (Toxicity/Dosage)-29 Genes

n  Immunotherapy-27 Genes

n  Hereditary Tumor Analysis-74 genes

n  Evaluation of Immunotherapy (TMB, MSI, TNB etc.)

l  Med1CDx ：601-Gene Panel for Solid Tumors

l  More NGS Panels for Solid Tumors

①    HRDetect CDx ：Homologous recombination deficiency (HRD) Test

n  CDx, medication guidance： ovarian cancer ，breast cancer，prostate cancer and pancreatic cancer PRAP inhibitor

n  Washington DC commons、NCCN guide，85 genes

n  ChinaMap database，over 41000 SNPs of Chinese population

n  Specific scoring algorithm, analyze LOH、TAI、LST，generate GIS score

②    panFGFx：Assays for FGFR Signaling

n  CDx, medication guidance: melanoma , NSCLC, renal cell carcinoma FGFR inhibitor

n  Customized probes，for CDx development